Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12885-017-3585-x.

Title:
Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer | BMC Cancer
Description:
There is evidence that some ovarian tumours evoke an immune response, which can be assessed by tumour infiltrating lymphocytes (TILs). To facilitate adoption of TILs as a clinical biomarker, a standardised method for their H&E visual evaluation has been validated in breast cancer. We sought to investigate the prognostic significance of TILs in a study of 953 invasive epithelial ovarian cancer tumour samples, both primary and metastatic, from 707 patients from the prospective population-based SEARCH study. TILs were analysed using a standardised method based on H&E staining producing a percentage score for stromal and intratumoral compartments. We used Cox regression to estimate hazard ratios of the association between TILs and survival. The extent of stromal and intra-tumoral TILs were correlated in the primary tumours (n = 679, Spearman’s rank correlation = 0.60, P < 0.001) with a similar correlation in secondary tumours (n = 224, Spearman’s rank correlation = 0.62, P < 0.001). There was a weak correlation between stromal TIL levels in primary and secondary tumour samples (Spearman’s rank correlation = 0.29, P < 0.001) and intra-tumoral TIL levels in primary and secondary tumour samples (Spearman’s rank correlation = 0.19, P = 0.0094). The extent of stromal TILs differed between histotypes (Pearson chi2 (12d.f.) 54.1, P < 0.0001) with higher levels of stromal infiltration in the high-grade serous and endometriod cases. A significant association was observed for higher intratumoral TIL levels and a favourable prognosis (HR 0.74 95% CI 0.55–1.00 p = 0.047). This study is the largest collection of epithelial ovarian tumour samples evaluated for TILs. We have shown that stromal and intratumoral TIL levels are correlated and that their levels correlate with clinical variables such as tumour histological subtype. We have also shown that increased levels of both intratumoral and stromal TILs are associated with a better prognosis; however, this is only statistically significant for intratumoral TILs. This study suggests that a clinically useful immune prognostic indicator in epithelial ovarian cancer could be developed using this technique.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Education
  • Health & Fitness
  • Science

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {šŸ”}

cancer, ovarian, tumour, article, tils, intratumoral, pubmed, stromal, levels, lymphocytes, google, scholar, til, study, epithelial, cas, primary, data, cells, tumours, immune, prognostic, infiltrating, correlation, clinical, prognosis, samples, table, tumorinfiltrating, search, association, response, method, secondary, serous, shown, access, evaluation, survival, cases, cell, cambridge, histotype, full, standardised, patients, spearmans, rank, effect, open,

Topics {āœ’ļø}

cytolytic t-cell responses article download pdf multi-variable cox regression anti-tumour immune response related subjects late-stage ovarian cancer tumor-infiltrating t-lymphocytes tumour histological subtype tumor-infiltrating lymphocyte levels paraffin-embedded tumour samples intra-tumoral infiltrating lymphocytes high-grade serous cases cd3+ tumor-infiltrating lymphocytes intra-tumoral til levels tumor-infiltrating plasma cells epithelial ovarian cancer invasive ovarian cancer cancer research uk intraepithelial cd8-positive secondary tumour sample full access high-grade serous tumour infiltrating lymphocytes privacy choices/manage cookies human ovarian cancer regional cancer registry standardised method based search clinical database mercedes jiminez-linan standard histopathology based secondary tumour samples creative commons license table 4 intra-tumoral retrieved including tumour bmc cancer 17 tumor-infiltrating lymphocytes cancer immunol immunother ovarian carcinoma disease-specific mortality ovarian tumours evoke tumor-infiltrating cd8+ multi-variable model methods study population lymphocytes predict survival global cancer statistics programmed cell death-1 omental tumour material predicts reduced survival estimate hazard ratios mononuclear lymphocytic infiltrate

Questions {ā“}

  • Immunotherapy for ovarian cancer: what's next?
  • Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?
  • Prognostic factors in ovarian cancer: how close are we to a complete picture?

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer
         description:There is evidence that some ovarian tumours evoke an immune response, which can be assessed by tumour infiltrating lymphocytes (TILs). To facilitate adoption of TILs as a clinical biomarker, a standardised method for their H&E visual evaluation has been validated in breast cancer. We sought to investigate the prognostic significance of TILs in a study of 953 invasive epithelial ovarian cancer tumour samples, both primary and metastatic, from 707 patients from the prospective population-based SEARCH study. TILs were analysed using a standardised method based on H&E staining producing a percentage score for stromal and intratumoral compartments. We used Cox regression to estimate hazard ratios of the association between TILs and survival. The extent of stromal and intra-tumoral TILs were correlated in the primary tumours (nĀ =Ā 679, Spearman’s rank correlationĀ =Ā 0.60, PĀ <Ā 0.001) with a similar correlation in secondary tumours (nĀ =Ā 224, Spearman’s rank correlationĀ =Ā 0.62, PĀ <Ā 0.001). There was a weak correlation between stromal TIL levels in primary and secondary tumour samples (Spearman’s rank correlationĀ =Ā 0.29, PĀ <Ā 0.001) and intra-tumoral TIL levels in primary and secondary tumour samples (Spearman’s rank correlationĀ =Ā 0.19, PĀ =Ā 0.0094). The extent of stromal TILs differed between histotypes (Pearson chi2 (12d.f.) 54.1, PĀ <Ā 0.0001) with higher levels of stromal infiltration in the high-grade serous and endometriod cases. A significant association was observed for higher intratumoral TIL levels and a favourable prognosis (HR 0.74 95% CI 0.55–1.00 pĀ =Ā 0.047). This study is the largest collection of epithelial ovarian tumour samples evaluated for TILs. We have shown that stromal and intratumoral TIL levels are correlated and that their levels correlate with clinical variables such as tumour histological subtype. We have also shown that increased levels of both intratumoral and stromal TILs are associated with a better prognosis; however, this is only statistically significant for intratumoral TILs. This study suggests that a clinically useful immune prognostic indicator in epithelial ovarian cancer could be developed using this technique.
         datePublished:2017-09-20T00:00:00Z
         dateModified:2017-09-20T00:00:00Z
         pageStart:1
         pageEnd:7
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12885-017-3585-x
         keywords:
            Tumour infiltrating lymphocytes (TILs)
            Epithelial ovarian cancer
            Standardised method
            Histological subtype
            Survival time
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3585-x/MediaObjects/12885_2017_3585_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3585-x/MediaObjects/12885_2017_3585_Fig2_HTML.gif
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Fiona R. James
               url:http://orcid.org/0000-0003-0824-6155
               affiliation:
                     name: Lancashire Teaching Hospitals Foundation NHS Trust
                     address:
                        name: Lancashire Teaching Hospitals Foundation NHS Trust, Lancashire, UK
                        type:PostalAddress
                     type:Organization
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mercedes Jiminez-Linan
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Pathology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jennifer Alsop
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marie Mack
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Honglin Song
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James D. Brenton
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paul D. P. Pharoah
               affiliation:
                     name:University of Cambridge
                     address:
                        name:Department of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. Raza Ali
               affiliation:
                     name:CRUK Cambridge Institute, University of Cambridge
                     address:
                        name:Department of Pathology, CRUK Cambridge Institute, University of Cambridge, Cambridge, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer
      description:There is evidence that some ovarian tumours evoke an immune response, which can be assessed by tumour infiltrating lymphocytes (TILs). To facilitate adoption of TILs as a clinical biomarker, a standardised method for their H&E visual evaluation has been validated in breast cancer. We sought to investigate the prognostic significance of TILs in a study of 953 invasive epithelial ovarian cancer tumour samples, both primary and metastatic, from 707 patients from the prospective population-based SEARCH study. TILs were analysed using a standardised method based on H&E staining producing a percentage score for stromal and intratumoral compartments. We used Cox regression to estimate hazard ratios of the association between TILs and survival. The extent of stromal and intra-tumoral TILs were correlated in the primary tumours (nĀ =Ā 679, Spearman’s rank correlationĀ =Ā 0.60, PĀ <Ā 0.001) with a similar correlation in secondary tumours (nĀ =Ā 224, Spearman’s rank correlationĀ =Ā 0.62, PĀ <Ā 0.001). There was a weak correlation between stromal TIL levels in primary and secondary tumour samples (Spearman’s rank correlationĀ =Ā 0.29, PĀ <Ā 0.001) and intra-tumoral TIL levels in primary and secondary tumour samples (Spearman’s rank correlationĀ =Ā 0.19, PĀ =Ā 0.0094). The extent of stromal TILs differed between histotypes (Pearson chi2 (12d.f.) 54.1, PĀ <Ā 0.0001) with higher levels of stromal infiltration in the high-grade serous and endometriod cases. A significant association was observed for higher intratumoral TIL levels and a favourable prognosis (HR 0.74 95% CI 0.55–1.00 pĀ =Ā 0.047). This study is the largest collection of epithelial ovarian tumour samples evaluated for TILs. We have shown that stromal and intratumoral TIL levels are correlated and that their levels correlate with clinical variables such as tumour histological subtype. We have also shown that increased levels of both intratumoral and stromal TILs are associated with a better prognosis; however, this is only statistically significant for intratumoral TILs. This study suggests that a clinically useful immune prognostic indicator in epithelial ovarian cancer could be developed using this technique.
      datePublished:2017-09-20T00:00:00Z
      dateModified:2017-09-20T00:00:00Z
      pageStart:1
      pageEnd:7
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12885-017-3585-x
      keywords:
         Tumour infiltrating lymphocytes (TILs)
         Epithelial ovarian cancer
         Standardised method
         Histological subtype
         Survival time
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3585-x/MediaObjects/12885_2017_3585_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-017-3585-x/MediaObjects/12885_2017_3585_Fig2_HTML.gif
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Fiona R. James
            url:http://orcid.org/0000-0003-0824-6155
            affiliation:
                  name: Lancashire Teaching Hospitals Foundation NHS Trust
                  address:
                     name: Lancashire Teaching Hospitals Foundation NHS Trust, Lancashire, UK
                     type:PostalAddress
                  type:Organization
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mercedes Jiminez-Linan
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Pathology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jennifer Alsop
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marie Mack
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Honglin Song
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James D. Brenton
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paul D. P. Pharoah
            affiliation:
                  name:University of Cambridge
                  address:
                     name:Department of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. Raza Ali
            affiliation:
                  name:CRUK Cambridge Institute, University of Cambridge
                  address:
                     name:Department of Pathology, CRUK Cambridge Institute, University of Cambridge, Cambridge, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:17
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name: Lancashire Teaching Hospitals Foundation NHS Trust
      address:
         name: Lancashire Teaching Hospitals Foundation NHS Trust, Lancashire, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Pathology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:University of Cambridge
      address:
         name:Department of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
         type:PostalAddress
      name:CRUK Cambridge Institute, University of Cambridge
      address:
         name:Department of Pathology, CRUK Cambridge Institute, University of Cambridge, Cambridge, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Fiona R. James
      url:http://orcid.org/0000-0003-0824-6155
      affiliation:
            name: Lancashire Teaching Hospitals Foundation NHS Trust
            address:
               name: Lancashire Teaching Hospitals Foundation NHS Trust, Lancashire, UK
               type:PostalAddress
            type:Organization
            name:University of Cambridge
            address:
               name:Department of Oncology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mercedes Jiminez-Linan
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Pathology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Jennifer Alsop
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Oncology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Marie Mack
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Oncology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Honglin Song
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Oncology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:James D. Brenton
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Oncology, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:Paul D. P. Pharoah
      affiliation:
            name:University of Cambridge
            address:
               name:Department of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
      name:H. Raza Ali
      affiliation:
            name:CRUK Cambridge Institute, University of Cambridge
            address:
               name:Department of Pathology, CRUK Cambridge Institute, University of Cambridge, Cambridge, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name: Lancashire Teaching Hospitals Foundation NHS Trust, Lancashire, UK
      name:Department of Oncology, University of Cambridge, Cambridge, UK
      name:Department of Pathology, University of Cambridge, Cambridge, UK
      name:Department of Oncology, University of Cambridge, Cambridge, UK
      name:Department of Oncology, University of Cambridge, Cambridge, UK
      name:Department of Oncology, University of Cambridge, Cambridge, UK
      name:Department of Oncology, University of Cambridge, Cambridge, UK
      name:Department of Oncology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
      name:Department of Pathology, CRUK Cambridge Institute, University of Cambridge, Cambridge, UK

External Links {šŸ”—}(126)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

4.48s.